Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood‐brain barrier
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Mucopolysaccharidosis Type I, Hurler's Syndrome, is a lysosomal storage disorder that affects the brain. The missing enzyme, α‐L‐iduronidase (IDUA), does not cross the blood‐brain barrier (BBB). To enable BBB transport of the enzyme, human IDUA was fused to the carboxyl terminus of the heavy chain of a chimeric monoclonal antibody (MAb) to the human insulin receptor (HIR). The HIRMAb crosses the BBB on the endogenous insulin receptor, and acts as a molecular Trojan horse to ferry into brain the IDUA. Transfection of COS cells resulted in high levels of IDUA enzyme activity both in the medium and in the intracellular space. The size of the fusion heavy chain, as measured with Western blotting and antibodies to either human IDUA or human IgG, was increased about 80 kDa, relative to the size of the heavy chain of the parent HIRMAb. The IDUA enzyme specific activity of the affinity purified HIRMAb‐IDUA fusion protein was 363 ± 37 U/µg protein, which is comparable to specific activity of recombinant IDUA. The accumulation of glycosoaminoglycans in Hurler fibroblasts was decreased 70% by treatment with the HIRMAb‐IDUA fusion protein. Confocal microscopy showed targeting of the fusion protein to the lysosome. The HIRMAb‐IDUA fusion protein bound with high affinity to the HIR, and was rapidly transported into the brain of the adult Rhesus monkey following intravenous administration. The HIRMAb‐IDUA fusion protein is a new treatment for Hurler's syndrome, which has been specifically engineered to cross the human BBB. Biotechnol. Bioeng. 2008;99: 475–484. © 2007 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pardridge, W. M. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2006.10.013 · Cited by 1,191
Self-citation
Cited by
Drug Transport across the Blood–Brain Barrier
Pardridge, W. M. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.126 · Cited by 1,994
Self-citationTranscytosis to Cross the Blood Brain Barrier, New Advancements and Challenges
Pulgar, V. M. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.01019 · Cited by 482
Targeting Receptor-Mediated Transport for Delivery of Biologics Across the Blood-Brain Barrier
Lajoie, J. M., & Shusta, E. V. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124852 · Cited by 399
Blood-Brain Barrier and Delivery of Protein and Gene Therapeutics to Brain
Pardridge, W. M. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00373 · Cited by 405
Self-citationOcular novel drug delivery: impacts of membranes and barriers
Barar, J., Javadzadeh, A. R., & Omidi, Y. (2008) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.5.5.567 · Cited by 308
Metadata
- Authors
- Boado, R. J., Zhang, Y., Zhang, Y., Xia, C., Wang, Y., & Pardridge, W. M.
- Venue
- Biotechnology and Bioengineering
- Publisher
- Wiley
- Published
- 2007-08-06
- Volume
- 99
- Issue
- 2
- Pages
- 475-484
- ISSN
- 0006-3592 (ISSN-L)
- 1097-0290
- OpenAlex
- W2097778362
- Cited by
- 142
- References
- 1
- FWCI
- 5.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.